Back to discover

Protein / target

Tumor protein p73

Encoded byTP73O15350Homo sapiensSwiss-Prot
UniProt: O15350Ensembl: ENSG00000078900HGNC: HGNC:12003NCBI Gene: 7161
Antibody-tractable
Druggability
GO CC high conf
1
Research papers

Protein at a glance

Biological role

Transcription cis-regulatory region binding

Strongest disease association

Sleep Initiation and Maintenance Disorders

Via encoding gene TP73 · Genetic evidence · score 0.47

Research activity

Emerging research

1 papers · latest 2024

Derived from structured UniProt, Open Targets and literature data on this page.

Protein profile

UniProt 2026_02

Canonical identity and biological annotation from UniProt.

Function overview

Participates in the apoptotic response to DNA damage.

View complete UniProt function annotation

Participates in the apoptotic response to DNA damage. Isoforms containing the transactivation domain are pro-apoptotic, isoforms lacking the domain are anti-apoptotic and block the function of p53 and transactivating p73 isoforms. May be a tumor suppressor protein. Is an activator of FOXJ1 expression (By similarity). It is an essential factor for the positive regulation of lung ciliated cell differentiation (PubMed:34077761)

Subcellular location

NucleusCytoplasm
Domains and Gene Ontology detail (34)

Domains & features

SAM

Gene Ontology

  • Cchromatin
  • Ccytosol
  • Cnucleoplasm
  • Cnucleus
  • FDNA-binding transcription activator activity, RNA polymerase II-specific
  • FDNA-binding transcription factor activity
  • FDNA-binding transcription factor activity, RNA polymerase II-specific
  • FDNA-binding transcription factor binding
  • Fidentical protein binding
  • FMDM2/MDM4 family protein binding
  • Fmetal ion binding
  • Fp53 binding

636 aa · 70 kDa · 11 isoforms

Biological roles

What this protein does, drawn together from its UniProt function, Gene Ontology terms and Reactome pathways.

Cell proliferation & survivalGOCell-cycle regulationGOTumour suppressionUniProtTranscriptional regulationGO
View supporting evidence

Cell proliferation & survival

  • ·negative regulation of cell population proliferation

Cell-cycle regulation

  • ·regulation of mitotic cell cycle

Tumour suppression

  • ·Participates in the apoptotic response to DNA damage. Isoforms containing the transactiv…

Transcriptional regulation

  • ·DNA-binding transcription activator activity, RNA polymerase II-specific
  • ·DNA-binding transcription factor activity
  • ·DNA-binding transcription factor activity, RNA polymerase II-specific
  • ·DNA-binding transcription factor binding

Concepts derived from UniProt GO Reactome — each badge above shows which sources supported that role.

Translational evidence

Open Targets 26

Why this target matters therapeutically, strongest evidence first. Disease associations are gene-level (via the gene that encodes this protein) and open into the full confidence synthesis; the development universe, tractability and safety annotations are target-level, from Open Targets.

Strongest disease associations · via encoding gene TP73

Gene-level evidence surfaced through the gene TP73that encodes this protein — not a direct protein–disease relationship. Ranked by Forefront's causal-directness weighting, so genetically- and clinically-evidenced diseases lead over ones that merely share the literature.

Sleep Initiation and Maintenance Disorders
0.47Limited support

Genetic evidence dominant · Open Targets 0.28

Seborrheic keratosis
0.47Limited support

Genetic evidence dominant · Open Targets 0.28

Skin Diseases
0.46Limited support

Genetic evidence dominant · Open Targets 0.28

Respiratory Insufficiency
0.43Limited support

Genetic evidence dominant · Open Targets 0.26

Skin Neoplasms
0.38Limited support

Genetic evidence dominant · Open Targets 0.23

View evidence synthesis (5)
Sleep Initiation and Maintenance DisordersLimited support
0.47
agreement 0.35–0.59
Genetic100%

Open Targets aggregate 0.28 · 1 independent evidence family

Seborrheic keratosisLimited support
0.47
agreement 0.35–0.59
Genetic100%

Open Targets aggregate 0.28 · 1 independent evidence family

Skin DiseasesLimited support
0.46
agreement 0.34–0.58
Genetic100%

Open Targets aggregate 0.28 · 1 independent evidence family

Respiratory InsufficiencyLimited support
0.43
agreement 0.31–0.55
Genetic100%

Open Targets aggregate 0.26 · 1 independent evidence family

Skin NeoplasmsLimited support
0.38
agreement 0.24–0.52
Genetic98%Literature2%

Open Targets aggregate 0.23 · 2 independent evidence families

The evidence agreement range shows how closely the independent evidence families agree — it is not a statistical confidence interval, and nothing here is fitted to outcome data. Derived from Open Targets evidence types under Forefront weighting; the per-type scores above show the calculation.

Show all associations
Neurodegenerative Diseases0.53
Sleep Initiation and Maintenance Disorders0.28
Seborrheic keratosis0.28
Skin Diseases0.28
Respiratory Insufficiency0.26
Skin Neoplasms0.23
Actinic keratosis0.22
Genetic Diseases, Inborn0.19
Neurodevelopmental Disorders0.11

Tractability

Antibodies — Emerging

Feasibility evidence (go cc high conf and human protein atlas loc) — no clinical-stage drug of this modality recorded.

Protein degraders — Emerging

Feasibility evidence (uniprot ubiquitination and database ubiquitination) — no clinical-stage drug of this modality recorded.

View underlying tractability evidence (4)
AB · GO CC high confAB · Human Protein Atlas locPR · UniProt UbiquitinationPR · Database Ubiquitination

Raw Open Targets tractability assessment buckets, by modality.

Research activity

1 papers · to 2024

Papers linked directly to this protein. This is the protein's own literature — descriptor-derived papers are kept separate below.

Most cited

Evolutionary trajectories of small cell lung cancer under therapy.84 cites

George J · Nature · 2024

Recent

Evolutionary trajectories of small cell lung cancer under therapy.

George J · Nature · 2024

Europe PMC papers linked directly to this protein.